X-Vax Technology, Inc.

X-Vax Technology, Inc. is a biotechnology company focused on developing innovative vaccine solutions to address infectious diseases and improve public health outcomes. Founded in 2015 and headquartered in Jupiter, US, X-Vax Technology, Inc. specializes in vaccine development.

The company has successfully completed four deals, with its most recent funding round being a Series A on July 18, 2019, which raised USD 9. 78 mn from investors including the Bill & Melinda Gates Foundation and Johnson & Johnson Innovation. Roger Pomerantz is the founder, and Ulf Wiinberg serves as CEO. X-Vax Technology, Inc.

specializes in delivering innovative vaccine solutions tailored to meet the specific needs of public health entities and healthcare providers. These offerings are designed to address critical challenges in infectious disease control, primarily targeting healthcare sectors across the US and other key global markets. The company emphasizes user-centric design and functionality, ensuring end-users benefit from enhanced efficacy and improved health outcomes. The company generates revenue through a structured model that includes partnerships and direct sales of its vaccine products.

Transactions typically involve healthcare providers engaging with the company to procure vaccines, which may be offered under various pricing plans. This diverse revenue stream enables X-Vax to maintain a robust financial foundation while serving a wide array of healthcare clients. X-Vax Technology, Inc. plans to expand its portfolio with new vaccine products scheduled for release in the upcoming fiscal year.

The company also aims to penetrate emerging markets in Asia and Europe by 2022, leveraging its recent Series A funding of USD 9. 78 mn raised in July 2019. This funding will be utilized to support research and development efforts, as well as to establish partnerships with local health organizations to facilitate market entry.